Panel de la FDA aprueba compuestos de cuatro péptidos

Panel de la FDA aprueba compuestos de cuatro péptidos

Negocios Salud Política

El Comité de Compounding de Farmacias de la FDA en Silver Spring, Maryland, votó para añadir cuatro péptidos experimentales — BPC-157, KPV, TB-500 y MOTS-c — a la lista de compuestos que pueden preparar las farmacias de compounding. La decisión siguió a una serie de reuniones que WIRED informó que la agencia había programado para revisar la posible reclasificación de varios péptidos. NPR señaló que el comité evaluaría la seguridad de siete péptidos inyectables populares, mientras que CNN indicó que la revisión consideraría su inclusión en la lista 503A Bulks.

Al Jazeera destacó la escasez de evidencia clínica y posibles conflictos de interés entre los miembros del panel. ABC News informó que la votación fue 8-6 a favor de incluir BPC-157, y NBC News informó posteriormente que se aprobó de forma estrecha la incorporación de los cuatro péptidos pese a objeciones de científicos. Ars Technica resumió que la recomendación de levantar las restricciones de fabricación se hizo a pesar de la falta de datos de seguridad y eficacia en humanos.

Actores

Food and Drug Administration (FDA) Mochi Health Myra Ahmad Hims & Hers Health Anant Vinjamoori Olympia Pharmaceuticals Joshua Fritzler RxConnexion Sapho Bio LegitScript Gerard Olson Amanecia Health Ann Czarnik Alliance for Pharmacy Compounding OnTop Labs Thomas Millman

Ubicaciones

Silver Spring, Maryland, United States

Artículos

24 de julio de 2026
1 en total
RFK Jr.'s hand-picked committee approves manufacture of peptides he uses
RFK Jr.'s hand-picked committee approves manufacture of peptides he uses

Ars Technica • 24 de jul 19:10

An FDA-organized committee voted to recommend removing manufacturing limits on four peptides, despite the absence of human safety and efficacy data, after the panel’s composition was altered earlier this year.

Credibilidad 71% Manip. 38% Centro
23 de julio de 2026
5 en total
An FDA Panel Just Endorsed These Unproven Peptides
An FDA Panel Just Endorsed These Unproven Peptides

WIRED • 23 de jul 23:45

An FDA advisory committee narrowly approved three of four peptides for inclusion on the agency's bulk-drug list, allowing compounding pharmacies to prepare them despite limited safety data.

Credibilidad 68% Manip. 12% Centro
FDA panel recommends easing restrictions on several peptides, including BPC-157
FDA panel recommends easing restrictions on several peptides, including BPC-157

NBC News • 23 de jul 23:40

The FDA’s Pharmacy Compounding Advisory Committee narrowly approved adding BPC-157, KPV, TB-500 and MOTS-c to a list of compounds that can be prepared by compounding pharmacies, despite objections from career scientists over insufficient data.

Credibilidad 72% Manip. 9% Centro
FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list
FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list

ABC News - Breaking News, Latest News and Videos • 23 de jul 18:38

The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to place BPC-157 on a drug-compounding list, a step toward prescription availability pending final FDA approval.

Credibilidad 72% Manip. 8% Centro
FDA panel considers easing peptide restrictions
FDA panel considers easing peptide restrictions

NPR • 23 de jul 09:00

The FDA's advisory committee will evaluate seven peptide compounds, including TB-500 and BPC-157, amid debate over their safety and potential market access.

Credibilidad 78% Manip. 12% Centro
FDA reviews BPC-157, TB-500 and other peptides favored by RFK Jr.
FDA reviews BPC-157, TB-500 and other peptides favored by RFK Jr.

AP News • 23 de jul 04:02

The Food and Drug Administration began a two-day meeting to review seven unapproved peptides promoted for muscle growth and injury recovery, amid disagreement between career scientists and industry-linked advisers.

Credibilidad 78% Manip. 28% Centro
22 de julio de 2026
3 en total
US regulators to weigh controversial peptides backed by RFK Jr
US regulators to weigh controversial peptides backed by RFK Jr

Al Jazeera • 22 de jul 20:52

The FDA's Pharmacy Compounding Advisory Committee will consider whether seven peptides marketed for weight loss, sleep and other uses can be produced by licensed pharmacies, amid concerns over limited clinical evidence and potential conflicts of interest on the panel.

Credibilidad 72% Manip. 8% Centro
The future of peptides in the US is about to become clearer. Here’s what you should know
The future of peptides in the US is about to become clearer. Here’s what you should know

CNN • 22 de jul 19:44

The FDA's Pharmacy Compounding Advisory Committee will meet to evaluate seven non-approved peptides for possible inclusion on the 503A Bulks List, a step that could allow licensed compounding pharmacies to dispense them under prescription.

Credibilidad 70% Manip. 8% Centro
Peptides get their regulatory closeup
Peptides get their regulatory closeup

NPR • 22 de jul 09:00

The FDA's Pharmacy Compounding Advisory Committee will meet to evaluate whether compounding pharmacies can produce seven widely used wellness peptides, amid concerns over limited clinical data.

Credibilidad 73% Manip. 10% Centro
21 de julio de 2026
1 en total
The Great Peptide Cash Grab Has Begun
The Great Peptide Cash Grab Has Begun

WIRED • 21 de jul 13:45

The FDA will hold a meeting on July 23-24 to consider reclassifying certain peptides, which could allow pharmacies to compound them, prompting telehealth firms and compounding pharmacies to prepare for possible market changes.

Credibilidad 71% Manip. 14% Centro

Eventos relacionados